Aims Vitamin D deficiency is prevalent in heart failure (HF), but its relevance in early stages of heart failure with preserved ejection fraction (HFpEF) is unknown. We tested the association of 25-hydroxyvitamin D [25(OH)D] serum levels with mortality, hospitalizations, cardiovascular risk factors, and echocardiographic parameters in patients with asymptomatic diastolic dysfunction (DD) or newly diagnosed HFpEF. Methods and results We measured 25(OH)D serum levels in outpatients with risk factors for DD or history of HF derived from the DIAST-CHF study. Participants were comprehensively phenotyped including physical examination, echocardiography, and 6 min walk test and were followed up to 5 years. Quality of life was evaluated by the Short Form 36 (SF-36) questionnaire. We included 787 patients with available 25(OH)D levels. Median 25(OH)D levels were 13.1 ng/mL, mean E/e 0 medial was 13.2, and mean left ventricular ejection fraction was 59.1%. Only 9% (n = 73) showed a left ventricular ejection fraction <50%. Fifteen per cent (n = 119) of the recruited participants had symptomatic HFpEF. At baseline, participants with 25(OH)D levels in the lowest tertile (≤10.9 ng/L; n = 263) were older, more often symptomatic (oedema and fatigue, all P ≤ 0.002) and had worse cardiac [higher N-terminal pro-brain natriuretic peptide (NT-proBNP) and left atrial volume index, both P ≤ 0.023], renal (lower glomerular filtration rate, P = 0.012), metabolic (higher uric acid levels, P < 0.001), and functional (reduced exercise capacity, 6 min walk distance, and SF-36 physical functioning score, all P < 0.001) parameters. Increased NT-proBNP, uric acid, and left atrial volume index and decreased SF-36 physical functioning scores were independently associated with lower 25(OH)D levels. There was a higher risk for lower 25(OH)D levels in association with HF, DD, and atrial fibrillation (all P ≤ 0.004), which remained significant after adjusting for age. Lower 25(OH)D levels (per 10 ng/mL decrease) tended to be associated with higher 5 year mortality, P = 0.05, hazard ratio (HR) Conclusions Lower 25(OH)D levels were associated with reduced functional capacity in patients with DD or HFpEF and were significantly predictive for an increased rate of cardiovascular hospitalizations, also after adjusting for age, NT-proBNP, and selected baseline characteristics and co-morbidities.
Introduction
Vitamin D deficiency is commonly observed, and the prevalence is as high as almost 50% among the elderly.
1,2
The main vitamin D source is sunlight-induced vitamin D production in the skin. Vitamin D deficiency can be caused by limited sun exposure and consequential reduced ultraviolet B-induced vitamin D production in the skin.
1,3
Naturally, after synthesis in the skin, vitamin D becomes metabolized by a hepatic hydroxylase into 25-hydroxyvitamin D [25(OH)D], which is the main circulating vitamin D metabolite and is used for the classification of vitamin D status by most guidelines. 3, 4 Furthermore, 25(OH)D becomes hydroxylated by a renal 1α-hydroxylase into calcitriol (1,25-dihydroxyvitamin D) , which is the most active vitamin D metabolite, which has a high affinity to the vitamin D receptor, and which is rather an indicator of calcium homeostasis and kidney function than a good indicator of vitamin D status.
1,3,4
Vitamin D suppresses activation of the cardiac reninangiotensin system and of the natriuretic peptides, regulates the extracellular matrix turnover, calcium flux, and myocardial contractility, and affects the differentiation and proliferation of cardiomyocytes, which may mediate antihypertrophic and antihypertensive effects of vitamin D and protect against myocardial dysfunction.
2, 3 Mice with a systemic knockout of the vitamin D receptor developed cardiac hypertrophy and dysfunction with increased activation of the cardiac renin-angiotensin system, and in vitamin D-deficient rats, cardiac hypertrophy with increased myocardial collagen content and shortening of the QT interval was also demonstrated.
3
A lack of vitamin D has been reported to be associated with increased cardiovascular risk and various diseases, including hypertension, diabetes, obesity, vascular inflammation, left ventricular (LV) hypertrophy, and congestive heart failure (HF).
5-8
Heart failure is a major health problem in our society. 9 Clinical studies demonstrated that a low vitamin D status is prevalent in patients with HF.
2,4,10,11 A significant proportion of patients with HF is marked by preserved left ventricular ejection fraction (LVEF) and diastolic dysfunction (DD). The prevalence of this subgroup, termed HF with preserved ejection fraction (HFpEF), accounts for more than 50% of all HF cases, and the prevalence of DD and HFpEF is increasing. [12] [13] [14] Several studies have already proved an association between vitamin D deficiency and a poor outcome in patients with HF and reduced ejection fraction (HFrEF). 4, 6, 10 In contrast, a correlation between vitamin D status and the outcome in patients with asymptomatic DD or HFpEF has not been investigated so far. Therefore, the aim of our study was to determine whether an insufficient vitamin D status is associated with poor prognosis (i.e. mortality and hospitalizations) in a large cohort of patients with asymptomatic DD or 
Methods

Patient population
We recruited outpatients aged 50 to 85 years in 2004 and 2005 for the prospective, multicentre, observational DIAST-CHF study, which is part of the German Competence Network of Heart Failure. The participants had either more than or equal to one risk factor(s) for DD (hypertension, diabetes mellitus, sleep apnea syndrome, and coronary artery disease) or a previous diagnosis or history of HF. Candidates were identified by primary care physicians. Exclusion criteria were unwillingness to participate or inability for logistic reasons. Detailed description of the study concept has been published previously.
15
For the present analysis, participants with missing data of diastolic function were excluded. Additionally, we excluded those patients in whom vitamin D parameter [serum levels of 25(OH)D] was not ascertainable. All study subjects gave written informed consent. The DIAST-CHF study complies with the Declaration of Helsinki and was approved by the responsible Ethics Committees.
Clinical assessment
All participants underwent a complete physical examination, electrocardiogram, echocardiography, standardized 6 min walk test, and blood sampling. Medical history, including signs and symptoms of HF, co-morbidities, and medication, was determined. Echocardiography, particularly comprehensive evaluation of diastolic function with tissue Doppler technics, was performed in accordance with the guidelines of the American Society of Echocardiography. 16 A standard operating procedure was used, and randomly chosen examinations were verified by the echo core laboratory of the Competence Network Heart Failure at the University of Essen. DD was determined as described previously. 
15
The primary outcome measurements of the present analysis of the DIAST-CHF study were 5 year mortality, hospitalization, and cardiovascular hospitalization. Differences in the primary outcome measures between the first and the upper tertiles of 25(OH)D were calculated with Kaplan-Meier curves (log-rank tests) and Cox proportional hazard regression models using crude models as well as models adjusted for potential confounders. Results are presented as hazard ratios (HRs) with 95% confidence intervals. A P-value ≤0.05 was considered statistically significant. Statistical analyses were performed with SPSS 17.0 software (SPSS Inc., Chicago, IL, USA).
Statistical analysis
Results
Study sample
25-hydroxyvitamin D serum levels were available in 787 outpatients of the DIAST-CHF study with risk factors for DD or with previous diagnosis of HF. Baseline characteristics, echocardiographic and exercise capacity parameters, of all patients and according to 25(OH)D tertiles (first tertile vs. the upper tertiles) are presented in Table 1 . The median 25(OH)D serum level was 13.1 ng/mL (interquartile range = 7.5). Overall, 33.4% (n = 263, first tertile) of the patients had 25(OH)D concentrations ≤10.9 ng/mL. The mean age was 67.2 years, 47% were female, and mean LVEF was 59.1%. The mean value of E/e 0 medial was 13.2, and 15% of the patients had HFpEF according to the Paulus criteria. Only 9% (n = 73) of all patients had a reduced LVEF <50%. Patients with lower 25(OH)D concentrations (≤10.9 ng/mL) were older (P = 0.002) and more symptomatic (oedema and fatigue, both P < 0.001; nocturnal cough, P = 0.039; New York Heart Association II-IV, P = 0.008) than those with 25(OH)D levels >10.9 ng/mL. Lower 25(OH)D levels were also associated with higher body mass index (P = 0.002) and heart rate (P < 0.001), lower glomerular filtration rate (P = 0.012) and HDL (P = 0.044), higher uric acid (P < 0.001), and higher NT-proBNP (P = 0.023). Patients with lower 25(OH)D also showed reduced exercise capacity (6 min walk distance and SF-36 physical functioning score, both P < 0.001), had higher values of left atrial volume index (LAVI) (P = 0.005), and showed HFpEF according to the Paulus criteria more often (P = 0.003). In addition, patients with lower 25(OH)D concentrations suffered from chronic obstructive pulmonary disease (P = 0.015) or atrial fibrillation (P = 0.024) more often and used angiotensin-converting enzyme inhibitors or angiotensin receptor blockers (P = 0.001), diuretics, and vitamin K antagonists or other anticoagulants (all P < 0.001) more frequently.
Selected baseline parameters, co-morbidities, drugs, and 25-hydroxyvitamin D serum level
In multiple linear regression analysis, increased values of NTproBNP (P = 0.001), uric acid (P < 0.001), and LAVI (P = 0.001) as well as decreased SF-36 physical functioning scores (P < 0.001) and New York Heart Association class >I (P = 0.026) were independent determinants of lower 25(OH)D levels (per 10 ng/mL decrease). These findings remained significant after adjusting for age (Table 2A) .
Logistic regression analysis showed a statistically higher risk for lower 25(OH)D levels (per 10 ng/mL decrease) in association with DD, OR 1.84 [1.24; 2.73]; P = 0.002, or HF (history of HF, verified by cardiologists or primary care physicians, OR 2.54 [1.73; 3.72]; P < 0.001). Furthermore, selected drugs and co-morbidities, notably the presence of atrial fibrillation, OR 3.2 [1.44; 7.10]; P = 0.004, were associated with decreased 25(OH)D levels. These associations remained significant after adjusting for age. The tested co-morbidities and drugs are completely listed in Table 2B . 
107 (14) 48 (18) 59 (11) 0.008 Oedema-N (%)
175 (22) Fisher's exact test for nominal data and t-test/Welch test for metric data. ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; COPD, chronic obstructive pulmonary disease; E/e 0 medial, mitral wave peak early filling velocity to (medial) mitral annular velocity ratio; GFR, glomerular filtration rate; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; IQR, interquartile range; LA, left atrium; LAVI, left atrium volume index; LV, left ventricle; LVD(ED), left ventricular end diastolic diameter; MDRD, modification of diet in renal disease equation for estimating glomular filtration rate LVEF, left ventricular ejection fraction; NTproBNP, N-terminal pro-brain natriuretic peptide; NYHA, New York Heart Association; PHQ-9, Patient Health Questionnaire-Depression module; SD, standard deviation; SF-36, 36-Item Short-Form Health Survey.
Vitamin D in DD and HFpEF
Prognostic value of 25-hydroxyvitamin D During 5 years of follow-up, 77 (9.8%) patients died, 227 (28.8%) patients were hospitalized, and 62 (7.9%) patients were lost to follow-up. There was no significant difference between the group with 25(OH)D level ≤10.9 ng/mL and the group that had 25(OH)D level >10.9 ng/mL relating to the endpoint mortality (log-rank test P = 0.142) (Figure 1) . Additionally, the number of first hospitalizations increased over the time, but we detected no significant difference between both 25(OH)D groups regarding the endpoint first hospitalization (log-rank test P = 0.172). However, cardiovascular hospitalization increased significantly in the lowest compared with the upper two 25(OH)D tertiles (log-rank test P = 0.012) (Figure 2) .
Multivariable Cox regression analysis showed that lower 25(OH)D concentrations (per 10 ng/mL decrease) tended to be associated with higher 5 year mortality, P = 0.05, HR = 1.55 [1.00; 2.42], but there was no significant association between lower 25(OH)D levels and first hospitalization, P = 0.28, HR = 1.14 [0.90; 1.46]. After adjusting for age, NT-proBNP, and several baseline characteristics, co-morbidities, and drugs, there was also no significant correlation between lower 25(OH)D levels and the endpoints 5 year mortality or first hospitalization. However, lower 25(OH)D concentrations (per 10 ng/mL decrease) were significantly and independently associated with first cardiovascular hospitalization, P = 0. Table 3 , Model 1). In contrast, increased NT-proBNP levels (per two-fold increase) had a predictive impact on 5 year mortality, P < 0. Table 3 , Model 2).
Discussion
To our knowledge, this is the first study to elucidate the association of 25(OH)D serum levels with mortality and hospitalizations as well as with cardiovascular risk factors and echocardiographic measures of LV function especially in patients with asymptomatic DD or HFpEF. The present study demonstrated that vitamin D deficiency, as defined as the lowest tertile, is highly prevalent in our cohort: 33.4% Figure 2 25-hydroxyvitamin D and cardiovascular (CV) hospitalization. Cardiovascular hospitalization increased significantly in the lowest (≤10 ng/mL, green) compared with the upper (>10 ng/mL, blue) two 25-hydroxyvitamin D tertiles (log-rank test P = 0.012). ¥ represents NT-proBNP, heart failure, diastolic dysfunction by Paulus, atrial fibrillation, oedema, diuretics, vitamin K antagonists or anticoagulants, uric acid, 6 min walk distance, Short Form 36 physical functioning scale, left atrium (end-systolic), and left atrium volume index. * represents vitamin D, heart failure, diastolic dysfunction by Paulus, atrial fibrillation, oedema, diuretics, vitamin K antagonists or anticoagulants, uric acid, 6 min walk distance, Short Form 36 physical functioning scale, left atrium (end-systolic), and left atrium volume index. CI, confidence interval; CV, cardiovascular; HR, hazard ratio; NT-proBNP, N-terminal pro-brain natriuretic peptide.
Vitamin D in DD and HFpEF (n = 263, first tertile) of all patients had 25(OH)D concentrations ≤10.9 ng/mL. Several previous studies reported vitamin D deficiency to be highly prevalent in HF patients 2, 4, 7, 10, 11, 19 and indicated poor outcome of these individuals. 4, 6, 7, 10, 19 There is no consensus about a definite cut-off level for vitamin D deficiency; nevertheless, 25(OH)D levels <10 ng/mL (multiply by 2.496 to convert ng/mL to nmol/L) are considered by several previous studies as definite vitamin D deficiency, which is comparable with our cut-off.
2,6,7
We found no significant association between the vitamin D status of patients with DD or HFpEF and the endpoints mortality and first hospitalization. However, cardiovascular hospitalization rates increased significantly with decreasing vitamin D serum level. Multivariable Cox regression analysis showed that lower 25(OH)D concentrations (per 10 ng/mL decrease) tended to be associated with higher 5 year mortality but not significantly with first hospitalization. However, lower 25(OH)D concentrations were significantly and independently associated with a first cardiovascular hospitalization of patients with DD or HFpEF and remained statistically significant after adjusting for age, baseline values of NT-proBNP, and selected baseline characteristics and comorbidities. Vitamin D deficiency seems to be a predictor for increased cardiovascular hospitalizations.
In contrast, increased NT-proBNP levels were predictive of 5 year mortality risk as well as of first cardiovascular hospitalizations. However, after adjusting for age, vitamin D, and selected baseline characteristic and co-morbidities, increased NT-proBNP concentration remained significant and independently associated only with 5 year mortality. NT-proBNP, which is actually an important marker in diagnosis and therapy of HF, seems to reflect the overall mortality risk in our analysis.
Several studies have already examined the association between vitamin D status and outcome in patients with HFrEF or HF in general and were predominantly in line with our results, according to a poor outcome in consequence of a lack of vitamin D. Liu 
22
In the present analyses, we could find a higher probability for the development of decreased 25(OH)D levels in case of DD or HF. Low vitamin D levels in these patients could be explained as a consequence of reduced sun exposure due to disease-related sedentary lifestyle, limited mobility, and reduced outdoor activities or in case of malnutrition.
2,20
Baseline parameters of NT-proBNP, uric acid, and LAVI, as well as selected co-morbidities and drugs, were independent determinants of lower 25(OH)D levels.
Our results provide the basis for future studies to further evaluate the significance of vitamin D as a marker for diagnosis and therapy of cardiovascular diseases, particularly asymptomatic DD and HFpEF. So far, the effects of the treatment with vitamin D supplements on asymptomatic DD and HFpEF are not known. Previous studies reported that vitamin D therapy is relatively easy, cheap, and safe. 3, 19 We need further trials to prove the effect of regular vitamin D supplementation in prevention or treatment of DD and HFpEF.
Limitations
A limitation of our study is that our data are based on a typical cardiovascular risk cohort, despite representing data from almost 800 individuals. Our findings are also limited by significantly different results in an individual level and compared with other studies that is due to the approach that patients were categorized accordingly to 25(OH)D levels. Furthermore, in our cohort, we did not consider possible seasonal variations of 25(OH)D. Although our findings were adjusted for a selection of potential confounders, other impacting factors, such as an unhealthy mode of life (sedentary lifestyle, reduced outdoor activities, and obesity), might have been overlooked. Therefore, the generalizability of our findings to other populations may be limited. Moreover, the observational nature of our work precludes final conclusions regarding causality. In contrast, the main strengths of our analysis are the use of standardized 25(OH)D, the inclusion of comprehensively characterized patients with DD and HFpEF, and the 5 year follow-up period.
Conclusions
Patients with lower levels of 25(OH)D and preserved LVEF were older and more symptomatic. They demonstrated reduced exercise capacity as well as manifested HFpEF significantly more often. Furthermore, decreased 25(OH)D concentrations were significantly and independently associated with first cardiovascular hospitalization and remained statistically significant after adjusting for age, NT-proBNP, and several co-morbidities and baseline characteristics. To elucidate whether vitamin D supplementation is useful for treatment and prevention of DD and HFpEF, further trials are needed.
